J. Goldman & CO LP Revance Therapeutics, Inc. Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
A detailed history of J. Goldman & CO LP transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 13,500 shares of RVNC stock, worth $34,695. This represents 0.02% of its overall portfolio holdings.
Number of Shares
13,500Holding current value
$34,695% of portfolio
0.02%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RVNC
# of Institutions
232Shares Held
82.1MCall Options Held
680KPut Options Held
896K-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.73MShares$14.7 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA4.78MShares$12.3 Million0.0% of portfolio
-
Fil LTD Hamilton, D04.19MShares$10.8 Million0.01% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ4.16MShares$10.7 Million0.49% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...